Metraipolis › archive › dc_700d2b645845
Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL) — Europe PMC PMID:41220107
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41220107
- DOI
- 10.1080/15384047.2025.2581831
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T16:00:42.949Z
- SHA-256 of the archived text
917f57a34cbedcb213cdb71440834a89a581b349bd49122a73d9d99257f1e9a7- Stable URL of this page
https://metraipolis.com/documento/dc_700d2b645845
How to cite
Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL) — Europe PMC PMID:41220107 — Europe PMC (en), https://europepmc.org/article/MED/41220107 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_700d2b645845 (Metraipolis archive dc_700d2b645845, sha256 917f57a34cbedcb213cdb71440834a89a581b349bd49122a73d9d99257f1e9a7)
BibTeX
@misc{dc700d2b645845,
title = {Potential therapeutic GSK-3β inhibitor 9-ING-41 is active in combination with venetoclax in double-hit lymphoma (DHL) — Europe PMC PMID:41220107},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41220107},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_700d2b645845; sha256 917f57a34cbedcb213cdb71440834a89a581b349bd49122a73d9d99257f1e9a7},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41220107. Agents can read the archived copy with the MCP tool read_document.